Leuven

Futó vizsgálatok

• Toboroz

  Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

  NCT07691970· 3. fázis· Forrás

• Toboroz

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· 3. fázis· Forrás

• Fut, nem toboroz

  Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

  NCT06681324· 2. fázis· Forrás

• Toboroz

  Observational Study Protocol: LIVER-R

  NCT06252753· Forrás

• Fut, nem toboroz

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· 3. fázis· Forrás

• Fut, nem toboroz

  A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.

  NCT05637112· Forrás

• Toboroz

  A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  NCT05123482· 1/2. fázis· Forrás

• Fut, nem toboroz

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

  NCT04512235· 3. fázis· Forrás

• Fut, nem toboroz

  Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

  NCT04590963· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

  NCT04482309· 2. fázis· Forrás

• Fut, nem toboroz

  Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  NCT04494425· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

  NCT03775486· 2. fázis· Forrás

• Fut, nem toboroz

  To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

  NCT03330847· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

  NCT02671435· 1/2. fázis· Forrás

• Fut, nem toboroz

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· 3. fázis· Forrás

• Fut, nem toboroz

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· 3. fázis· Forrás

• Fut, nem toboroz

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· 3. fázis· Forrás

• Fut, nem toboroz

  Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

  NCT01843374· 2. fázis· Forrás

• Fut, nem toboroz

  Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

  NCT01081951· 2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Lupus (SLE)1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhtestrák1 toboroz
• Petefészekrák1 toboroz
• Prosztatarák1 toboroz
• Szisztémás szklerózis (szkleroderma)1 toboroz
• Tüdőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

  NCT05347693· 4. fázis· Forrás

• Lezárult

  Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

  NCT04986202· 2/3. fázis· Forrás

• Lezárult

  Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium

  NCT04221802· Forrás

• Lezárult

  Durvalumab Long-Term Safety and Efficacy Study

  NCT04078152· 4. fázis· Forrás

• Lezárult

  Long-Term Evaluation of BIIB067 (Tofersen)

  NCT03070119· 3. fázis· Forrás

• Lezárult

  Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

  NCT02197234· 1. fázis· Forrás

• Lezárult

  AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02296125· 3. fázis· Forrás